scispace - formally typeset
Open AccessJournal ArticleDOI

A Recombinant Peptide, Hirudin, Potentiates the Inhibitory Effects of Stealthy Liposomal Vinblastine on the Growth and Metastasis of Melanoma

Reads0
Chats0
TLDR
Administration of recombinant hirudin followed by giving stealthy liposomal vinblastine may be beneficial for inhibiting the growth and metastasis of melanoma in vivo.
Abstract
The metastasis of tumor cells is one of the major obstacles to successful clinical therapy. A treatment strategy by incorporating a specific inhibitor of thrombin, recombinant hirudin with stealthy liposomal vinblastine, was used in this study for inhibiting the metastasis of tumor cells and enhancing the efficacy of anti-tumor agents. In vitro cytotoxicity, cell adhesion to extracellular matrix (ECM) proteins, and cell invasion and migration assays were performed on human A375 melanoma cell line. In vivo measurement of coagulation parameters, inhibition of tumor growth, and inhibition of metastasis were assessed in female BALB/c mice. In vitro, vinblastine or stealthy liposomal vinblastine alone was effective to inhibit the growth of A375 cells. On the contrary, hirudin had no influence on either cytotoxicity when treating with hirudin alone or hirudin plus vinblastine. In addition, in vitro results showed that hirudin had no impact on the adhesion of tumor cells to extracellular matrix proteins, and metastasis and invasion of tumor cells. In mice, hirudin significantly inhibited the activity of thrombin. Furthermore, administered at the initial implantation of murine B16 melanoma cells, hirudin evidently delayed the growth of tumor, and depressed the occurrence of experimental lung metastasis. A subsequent administration of stealthy liposomal vinblastine resulted in further inhibiting growth and metastasis of tumor, indicating that hirudin plus stealthy liposomal vinblastine exhibited a significant anti-metastasis effect and slightly potent effect against tumor growth as compared with stealthy liposomal vinblastine alone. In conclusion, administration of recombinant hirudin followed by giving stealthy liposomal vinblastine may be beneficial for inhibiting the growth and metastasis of melanoma in vivo. The likely mechanism could be associated with inhibition of thrombin after administration of hirudin.

read more

Citations
More filters
Journal ArticleDOI

Mitochondrial targeting topotecan-loaded liposomes for treating drug-resistant breast cancer and inhibiting invasive metastases of melanoma.

TL;DR: The mitochondrial targeting topotecan-loaded liposomes had a stronger inhibitory effect on the resistant tumor spheroids in vitro, enhanced accumulation in resistant MCF-7/adr cell xenografts in mice, and having a marked anti-metastastic effect on a naturally resistant B16 melanoma metastatic model in mice.
Journal ArticleDOI

Natural products with therapeutic potential in melanoma metastasis

TL;DR: This paper systematically and critically surveys all natural products with direct in vitro and in vivo pharmacological effects on migration and/or metastasis of melanoma cells and maps the mechanisms of action for these underexploited properties.
Journal ArticleDOI

Thrombin—unique coagulation system protein with multifaceted impacts on cancer and metastasis

TL;DR: Though a great deal is known regarding the role of thrombin in cancer dissemination, there are new data for multiple throm bin-mediated events that justify devoting focus to this topic with a comprehensive approach.
Journal ArticleDOI

A role for thrombin in the initiation of the immune response to therapeutic factor VIII.

TL;DR: Data support the hypothesis that formation of thrombin through the procoagulant activity of FVIII is necessary to induce costimulation for the immune response to FV III treatment.
Journal ArticleDOI

Antiplatelet agents for cancer treatment: a real perspective or just an echo from the past?

TL;DR: The controversies around antiplatelet agents justify insight into the subject to establish what, if any, role platelet-directed therapy has in the continuum of anticancer management.
References
More filters
Journal ArticleDOI

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

TL;DR: A tetrazolium salt has been used to develop a quantitative colorimetric assay for mammalian cell survival and proliferation and is used to measure proliferative lymphokines, mitogen stimulations and complement-mediated lysis.
Journal Article

Vascular Permeability in a Human Tumor Xenograft: Molecular Size Dependence and Cutoff Size

TL;DR: Tumor vessels in the model found that tumor vessels in this model were permeable to liposomes of up to 400 nm in diameter, suggesting that the cutoff size of the pores is between 400 and 600nm in diameter.
Journal ArticleDOI

Activation of blood coagulation in cancer: Trousseau's syndrome revisited

Frederick R. Rickles, +1 more
- 01 Jul 1983 - 
TL;DR: On a passe en revue les diverses indications cliniques, histologiques, pharmacologiques and physiopathologiques confirmant l'existence d'une relation etroite entre les anomalies de the coagulation du sang and la biologie du cancer.

United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition)

TL;DR: The United Kingdom Coordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (Second Edition) as discussed by the authors have been widely used in the UK, as well as having an influence overseas.
Journal Article

Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes.

TL;DR: Data from 17 patients with locally advanced cancers studied strongly support the development of pegylated liposomal agents for the treatment of solid tumors, particularly those of the head and neck.
Related Papers (5)